DB:BON

Stock Analysis Report

Executive Summary

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.

Snowflake

Fundamentals

6 star dividend payer with flawless balance sheet.

Risks

  • Boiron has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Boiron's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.3%

DB:BON

1.2%

DE Pharmaceuticals

1.8%

DE Market


1 Year Return

-45.3%

DB:BON

1.9%

DE Pharmaceuticals

-3.5%

DE Market

BON underperformed the Pharmaceuticals industry which returned 1.9% over the past year.

BON underperformed the Market in Germany which returned -3.5% over the past year.


Share holder returns

BONIndustryMarket
7 Day-8.3%1.2%1.8%
30 Day-12.2%6.9%8.6%
90 Day-15.1%17.2%3.3%
1 Year-43.2%-45.3%5.3%1.9%-0.5%-3.5%
3 Year-58.5%-61.6%-4.7%-12.7%20.6%10.3%
5 Year-41.9%-48.2%-7.0%-18.6%30.7%12.8%

Price Volatility Vs. Market

How volatile is Boiron's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Boiron undervalued based on future cash flows and its price relative to the stock market?

33%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Boiron's share price is below the future cash flow value, and at a moderate discount (> 20%).

Boiron's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Boiron is good value based on earnings compared to the DE Pharmaceuticals industry average.

Boiron is good value based on earnings compared to the Germany market.


Price Based on Expected Growth

Boiron earnings are not expected to grow next year, we can't assess if its growth is good value.


Price Based on Value of Assets

Boiron is good value based on assets compared to the DE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Boiron expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

-0.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Boiron's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Boiron's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Boiron's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.

Boiron's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.

Boiron's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Boiron is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Boiron performed over the past 5 years?

-8.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Boiron's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

Boiron's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Boiron's 1-year earnings growth is negative, it can't be compared to the DE Pharmaceuticals industry average.


Return on Equity

Boiron has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Boiron used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Boiron's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Boiron's financial position?


Financial Position Analysis

Boiron is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Boiron's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Boiron's level of debt (1.8%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (2.3% vs 1.8% today).

Debt is well covered by operating cash flow (826.7%, greater than 20% of total debt).

Boiron earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 45x debt.


Next Steps

Dividend

What is Boiron's current dividend yield, its reliability and sustainability?

3.37%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Boiron's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.4%).

Boiron's dividend is above the markets top 25% of dividend payers in Germany (3.85%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are covered by earnings (1.4x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (2.1x coverage).


Next Steps

Management

What is the CEO of Boiron's salary, the management and board of directors tenure and is there insider trading?

5.9yrs

Average management tenure


CEO

Valérie Lorentz-Poinsot (50yo)

0.7yrs

Tenure

€2,438,693

Compensation

Ms. Valerie Lorentz-Poinsot serves as General Manager and Director of Development of Boiron SA and served as its Deputy General Manager since July 01, 2011. Ms. Lorentz-Poinsot has been an Executive Direct ...


CEO Compensation Analysis

Valérie's remuneration is higher than average for companies of similar size in Germany.

Valérie's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

5.9yrs

Average Tenure

61yo

Average Age

The average tenure for the Boiron management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

16.8yrs

Average Tenure

72yo

Average Age

The average tenure for the Boiron board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Christian Boiron (71yo)

    Director

    • Tenure: 45.8yrs
    • Compensation: €2.75m
  • Bruno Grange (66yo)

    International Controller & Director

    • Tenure: 17.3yrs
    • Compensation: €16.22k
  • Fabrice Rey

    Group Treasurer

    • Tenure: 17.8yrs
  • Valérie Lorentz-Poinsot (50yo)

    General Manager & Executive Director

    • Tenure: 0.7yrs
    • Compensation: €2.44m
  • Jean-Christophe Bayssat (56yo)

    Deputy GM

    • Tenure: 3.7yrs
    • Compensation: €1.18m

Board Members

  • Michel Bouissou (77yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: €45.63k
  • Christian Boiron (71yo)

    Director

    • Tenure: 45.8yrs
    • Compensation: €2.75m
  • Bruno Grange (66yo)

    International Controller & Director

    • Tenure: 17.3yrs
    • Compensation: €16.22k
  • Thierry Boiron (58yo)

    Chairman of the Board of Directors

    • Tenure: 8.2yrs
    • Compensation: €848.22k
  • Jean-Pierre Boyer (73yo)

    Director

    • Tenure: 19.3yrs
    • Compensation: €31.77k
  • Michèle Boiron (74yo)

    Director

    • Tenure: 23yrs
    • Compensation: €119.46k
  • Jacky Abécassis (77yo)

    Director

    • Tenure: 32.3yrs
    • Compensation: €13.03k
  • Christine Boyer-Boiron (75yo)

    Director

    • Tenure: 16.3yrs
    • Compensation: €13.03k
  • Stéphanie Chesnot (47yo)

    Director

    • Tenure: 9.5yrs
    • Compensation: €31.77k
  • Valérie Lorentz-Poinsot (50yo)

    General Manager & Executive Director

    • Tenure: 0.7yrs
    • Compensation: €2.44m

Company Information

Boiron SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Boiron SA
  • Ticker: BON
  • Exchange: DB
  • Founded: 1932
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €585.758m
  • Shares outstanding: 17.51m
  • Website: https://www.boiron.com

Number of Employees


Location

  • Boiron SA
  • 2, avenue de l’Ouest Lyonnais
  • Messimy
  • Rhône-Alpes
  • 69510
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BOIR.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
BOIENXTPA (Euronext Paris)YesOrdinary SharesFREURJan 1992
BONDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
0DTFLSE (London Stock Exchange)YesOrdinary SharesGBEURJan 1992
BOIPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJan 1992

Biography

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded home ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/14 20:56
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.